AFC-HD AMS Life Science Co., Ltd.
Stock Price Chart
2026/08/21 UpdatedPrice Trend
2026/08/21 UpdatedPrice & Trading Details
2026/08/21 UpdatedPRICE
TRADING
Shareholder Composition
Updated 2026/08/01Dividend History
Updated 2026/08/23| Year | Dividend | Change |
|---|---|---|
| 2026 | ¥18 | -47.1% |
| 2025 | ¥34 | +13.3% |
| 2024 | ¥30 | +9.1% |
| 2023 | ¥28 | -8.3% |
| 2022 | ¥30 | - |
Financial Performance
2026/08/23 UpdatedRevenue & Profit
Margins
Cash Flow
Financial Health
| 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | ¥23,025M | ¥25,579M | ¥30,185M | ¥32,655M |
| Gross Profit | ¥8,583M | ¥9,323M | ¥10,492M | ¥11,261M |
| Operating Income | ¥1,015M | ¥1,636M | ¥1,916M | ¥2,410M |
| Pretax Income | ¥1,293M | ¥1,604M | ¥2,012M | ¥2,402M |
| Net Income | ¥735M | ¥1,103M | ¥1,252M | ¥1,449M |
| EPS | ¥52.08 | ¥78.46 | - | ¥102.97 |
| Operating Margin | 4.41% | 6.40% | 6.35% | 7.38% |
| Balance Sheet | ||||
| Total Assets | ¥37,349M | ¥41,072M | ¥47,031M | ¥48,727M |
| Total Equity | ¥12,439M | ¥13,109M | ¥13,934M | ¥15,076M |
| Total Liabilities | ¥24,910M | ¥27,963M | ¥33,097M | ¥33,650M |
| Cash | ¥10,378M | ¥11,182M | ¥12,173M | ¥11,303M |
| Interest-bearing Debt | ¥17,135M | ¥19,538M | ¥22,892M | ¥23,913M |
| Equity Ratio | 33.31% | 31.92% | 29.63% | 30.94% |
| D/E Ratio | 1.38 | 1.49 | 1.64 | 1.59 |
| Cash Flow | ||||
| Operating CF | ¥1,492M | ¥865M | ¥1,540M | ¥1,787M |
| Investing CF | -¥1,078M | -¥1,946M | -¥2,761M | -¥3,327M |
| Financing CF | ¥1,160M | ¥1,881M | ¥2,232M | ¥667M |
| Free CF | ¥534M | -¥1,074M | -¥1,867M | -¥1,752M |
| Efficiency | ||||
| ROE | 5.91% | 8.41% | 8.99% | 9.61% |
| ROA | 1.97% | 2.68% | 2.66% | 2.97% |
Latest IR Information
-
Notice Regarding Increase in Year-end Dividend for the Fiscal Year Ending August 2026
Increase year-end dividend forecast for the fiscal year ending August 2026 to 22 yen, up 4 yen YoY. Scheduled for presentation at the Ordinary General Meeting of Shareholders on November 25, 2026.
Read more -
【AFC-Hd Amus Life Sciences】Q3 2026 Financial Results ｜ Revenue approximately JPY 2.53 billion (YoY +2.2%)
For the third quarter of the fiscal year ending August 2026, revenue was approximately JPY 2.53 billion, a 2.2% increase YoY. Strong performance in pharmaceutical and healthcare businesses led to sustained revenue growth, while total net income was JPY 117...
Read more -
[Saika-ya] Notice on the Status of Share Buyback and Cancellation
Discloses the purpose and progress of the share buyback, the total shares acquired and total consideration, and future handling. Items as of June 2026 are described, including plans to acquire 20,000 shares by the end of July, suggesting it may...
Read more -
Notice Regarding Resolution on Acquisition of Treasury Shares by Consolidated Subsidiary Saikaya Co., Ltd.
Read more -
Notice of Completion of Exercise and Monthly Status of the First Callable Stock Acquisition Rights (with Exercise Price Adjustment Clause) Issued to Third Parties through the Consolidated Subsidiary Sakaeya Co., Ltd.
Today, consolidated subsidiary Saikaya announced completion of the first exercise of stock acquisition rights through third-party allotment. The number of issued shares is 8,439,350, capital stock is 936,088,430 yen, and no remaining rights as of exercise completion. With a monthly...
Read more
Latest News (5 items)
Company Information
About
AFC-HD AMS Life Science Co., Ltd. operates as an original equipment manufacturer of health foods and cosmetics. The company operates through five segments: Healthcare, Pharmaceutical, Department Store, Food and Beverage, and Other Business. The Healthcare segment manufactures, sells, and supplies OEM health foods, such as tablets, capsules, granules, soft drinks, and jelly; and cosmetics, including skin care and hair care products. This segment also operates as an advertising agency focused on planning and producing health information programs, and publishing health information magazines. The Pharmaceutical segment manufactures and sells Chinese herbal medicine, over-the-counter medicines, and generic medicines. The Department Store segment engages in the wholesale of watches, jewelry, and precious metal products. The Food and Beverage segment operates restaurants. The Other Business segment engages in the real estate buying, selling, management, rental, and intermediary business; construction industry; tourism, travel and hotel industry; and school lunch business. AFC-HD AMS Life Science Co., Ltd. was founded in 1969 and is headquartered in Shizuoka, Japan.
